Duvelisib - Infinity Pharmaceuticals

Drug Profile

Duvelisib - Infinity Pharmaceuticals

Alternative Names: ABBV-954; INK-1197; IPI-145

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intellikine
  • Developer AbbVie; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Verastem
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Nonsteroidal anti-inflammatories; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase II Peripheral T-cell lymphoma
  • Phase I Lymphoma; T cell lymphoma
  • Preclinical Solid tumours
  • No development reported Haematological malignancies
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 12 Dec 2017 Verastem plans the BRIO phase II trial for Chronic lymphocytic leukaemia and lymphoma in December 2017 (NCT03370185)
  • 11 Dec 2017 Efficacy and adverse events data from a phase I trial in T-cell lymphoma released by Verastem
  • 10 Dec 2017 Phase-II clinical trials in Peripheral T-cell lymphoma (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top